Two doses of a new COVID-19 vaccine from Sanofi and GSK were 100% effective against severe disease and hospitalizations, the companies announced Wednesday. The vaccine was also 75% effective against moderate-to-severe disease and 58% effective against symptomatic disease in a Phase 3 clinical trial. And when used as a booster dose after one of the… read on > read on >







